Postherpetic Neuralgia (PHN) is a heterogeneous and complex pain syndrome that involves various pain mechanisms. It is believed that PHN patients could be classified into different sensory profiles using quantitative sensory testing. Because no standardized, comprehensive sensory assessment easily performed at bedside exists for PHN, we developed a Bedside Sensory Testing Kit for PHN (BSTK-PHN) to classify patients with PHN based on presence of peripheral and/or central sensitization. The kit was tested in a usability and informal (not powered) reliability study in 12 PHN patients. Subjects completed a neuropathic pain questionnaire and underwent sensory testing with the BSTK-PHN, which involves measuring (i) static and dynamic mechanical allodynia using a pressure algometer, (ii) punctate hyperalgesia via pinprick, (iii) low-threshold mechanoreceptive function using von Frey filaments; (iv) cold allodynia using a brass rod; (v) wind-up to temporal summation using the von Frey filaments; and (vi) diffuse noxious inhibitory control (DNIC) after heterotopic noxious conditioning stimulation (HNCS) using a pressure algometer. The BSTK-PHN assessments had a highly acceptable level of tolerability and usability for both subjects and investigators. Inter-rater reliability (kappa analysis) was above the pre-specified acceptability threshold for all assessments of the BSTK-PHN (>0.70), except for the DNIC, which was slightly below 0.70. Subjects appeared to cluster into discrete subgroups (based on the presence/absence of deafferentation, peripheral or central sensitization, and descending modulation) according to BSTK-PHN findings, though not with a high level of reliability between investigators. Further research in a larger sample is warranted to define a reliable algorithm for classification of PHN patients into subgroups based on sensory profiles. Overall, the BSTK-PHN is a convenient, reliable sensory testing tool for the classification of PHN patients into putative pain mechanism subgroups in PHN clinical trials. This study was supported by Merck. Postherpetic Neuralgia (PHN) is a heterogeneous and complex pain syndrome that involves various pain mechanisms. It is believed that PHN patients could be classified into different sensory profiles using quantitative sensory testing. Because no standardized, comprehensive sensory assessment easily performed at bedside exists for PHN, we developed a Bedside Sensory Testing Kit for PHN (BSTK-PHN) to classify patients with PHN based on presence of peripheral and/or central sensitization. The kit was tested in a usability and informal (not powered) reliability study in 12 PHN patients. Subjects completed a neuropathic pain questionnaire and underwent sensory testing with the BSTK-PHN, which involves measuring (i) static and dynamic mechanical allodynia using a pressure algometer, (ii) punctate hyperalgesia via pinprick, (iii) low-threshold mechanoreceptive function using von Frey filaments; (iv) cold allodynia using a brass rod; (v) wind-up to temporal summation using the von Frey filaments; and (vi) diffuse noxious inhibitory control (DNIC) after heterotopic noxious conditioning stimulation (HNCS) using a pressure algometer. The BSTK-PHN assessments had a highly acceptable level of tolerability and usability for both subjects and investigators. Inter-rater reliability (kappa analysis) was above the pre-specified acceptability threshold for all assessments of the BSTK-PHN (>0.70), except for the DNIC, which was slightly below 0.70. Subjects appeared to cluster into discrete subgroups (based on the presence/absence of deafferentation, peripheral or central sensitization, and descending modulation) according to BSTK-PHN findings, though not with a high level of reliability between investigators. Further research in a larger sample is warranted to define a reliable algorithm for classification of PHN patients into subgroups based on sensory profiles. Overall, the BSTK-PHN is a convenient, reliable sensory testing tool for the classification of PHN patients into putative pain mechanism subgroups in PHN clinical trials. This study was supported by Merck.